Protective Effect of FR183998, a Na〔+〕/H〔+〕 Exchange Inhibitor, Against Postischemic Injury After Normothermic and Prolonged Hypothermic Ischemia in Isolated Perfused Rat Hearts

DOI Web Site Web Site Web Site PubMed 参考文献39件
  • Ohara Fumihiro
    Department of Cardiovascular Disease, Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd.
  • Yamamoto Nobuhiro
    Department of Cardiovascular Disease, Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd.
  • Maeda Kazuhiro
    Research Planning, Fujisawa Pharmaceutical Co., Ltd.
  • Ozaki Toru
    Department of Cardiovascular Disease, Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd.
  • Seki Jiro
    Department of Cardiovascular Disease, Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd.
  • Goto Toshio
    Department of Cardiovascular Disease, Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd.

書誌事項

タイトル別名
  • Protective Effect of FR183998, a Na+/H+ Exchange Inhibitor, Against Postischemic Injury After Normothermic and Prolonged Hypothermic Ischemia in Isolated Perfused Rat Hearts.

この論文をさがす

抄録

Inhibition of Na+/H+ exchanger has been reported to protect hearts from ischemia and reperfusion injury. However, the effect of Na+/H+ exchange inhibition on hypothermic ischemic injury has not been extensively studied and the results are inconsistent. The purpose of this study was to investigate whether inhibition of Na+/H+ exchange with FR183998 (5-(2,5-dichlorothiphen-3-yl)-3-[(2-dimethylaminoethyl)carbamoyl]benzoylguanidine dihydrochloride), a potent Na+/H+ exchange inhibitor, would show protective effects against postischemic cardiac dysfunction after hypothermic as well as normothermic ischemia and furthermore, after hypothermic cardioplegic arrest in isolated rat hearts. FR183998 (3.2 × 10−8 – 3.2 × 10−7 M) improved post-ischemic recovery of left ventricular developed pressure and suppressed the increase of left ventricular end diastolic pressure in a dose-dependent manner, after not only 45 min of normothermic ischemia but also 6 h of hypothermic ischemia. Furthermore, FR183998 (10−7 – 10 −6 M) significantly reduced creatine kinase release during reperfusion after 3 h of hypothermic ischemia with cardioplegia. These results indicate that FR183998 has a potent protective effect on postischemic cardiac dysfunction after normothermic and hypothermic ischemia, and also on reperfusion injury after hypothermic cardioplegic arrest, suggesting that its effect would be additive to cardioplegia.

収録刊行物

  • Jpn.J.Pharmacol.

    Jpn.J.Pharmacol. 87 (2), 110-116, 2001

    公益社団法人 日本薬理学会

参考文献 (39)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ